What safety concern arises when combining triptans with SSRIs/SNRIs or MAO inhibitors?

What safety concern arises when combining triptans with SSRIs/SNRIs or MAO inhibitors?

• A. Potential serotonin syndrome; monitor for hyperthermia, agitation, autonomic instability; avoid with MAO inhibitors
• B. No significant interactions; can combine freely
• C. Increased risk of nephrotoxicity
• D. Excessive sedation

Answer: (A)

The safety concern is the risk of serotonin syndrome from added serotonergic activity. Triptans act on 5-HT receptors to treat migraine, but SSRIs/SNRIs increase serotonin levels in the brain, and MAO inhibitors prevent breakdown of serotonin. When these are combined, there can be an excessive serotonergic effect that triggers serotonin syndrome. Serotonin syndrome can range from mild to life-threatening and includes mental status changes (agitation, confusion), autonomic instability (fever, rapid heart rate, high blood pressure, sweating), and neuromuscular symptoms (tremor, myoclonus, hyperreflexia). Because MAO inhibitors produce a stronger and more dangerous interaction, the combination with triptans is avoided or requires careful management and timing. Other options aren’t the primary safety issue here: nephrotoxicity isn’t a known major risk with this combination, and excessive sedation isn’t the hallmark concern. The key point is the potential for serotonin syndrome due to additive serotonergic effects.

The safety concern is the risk of serotonin syndrome from added serotonergic activity. Triptans act on 5-HT receptors to treat migraine, but SSRIs/SNRIs increase serotonin levels in the brain, and MAO inhibitors prevent breakdown of serotonin. When these are combined, there can be an excessive serotonergic effect that triggers serotonin syndrome.

Serotonin syndrome can range from mild to life-threatening and includes mental status changes (agitation, confusion), autonomic instability (fever, rapid heart rate, high blood pressure, sweating), and neuromuscular symptoms (tremor, myoclonus, hyperreflexia). Because MAO inhibitors produce a stronger and more dangerous interaction, the combination with triptans is avoided or requires careful management and timing.

Other options aren’t the primary safety issue here: nephrotoxicity isn’t a known major risk with this combination, and excessive sedation isn’t the hallmark concern. The key point is the potential for serotonin syndrome due to additive serotonergic effects.